Overview
- Teva reported adjusted third-quarter earnings of $0.78 per share on $4.48 billion in revenue, beating FactSet estimates of $0.68 and $4.38 billion.
- The company raised its 2025 sales guidance for Austedo to $2.05 billion–$2.15 billion, citing robust demand for the movement‑disorders therapy.
- Teva trimmed the low end of its full‑year revenue outlook to a range of $16.8 billion–$17.0 billion, reshaping the company‑level sales guide.
- Management increased full‑year adjusted EPS guidance to $2.55–$2.65, aligning closely with analysts’ $2.61 consensus.
- Shares jumped about 12% in premarket trading to $22.91, with MarketSurge flagging a breakout from a cup‑with‑handle base.